RajanSaggarMD

Pulmonology • Los Angeles, CA

Critical Care Medicine

Assistant Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Saggar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Saggar's full profile

Already have an account?

Office
200 Medical Plz
# 365 B
Los Angeles, CA 90095
Phone+1 310-825-6654

Fax+1 310-794-9718

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2007
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1999 - 2002
Medical College of WisconsinClass of 1999

Certifications & Licensure

CA State Medical License 2002 - 2026
WI State Medical License 2001 - 2003
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation Start of enrollment: 2006 Jan 01
Withdrawn
Phase 3
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Start of enrollment: 2007 Feb 01
Withdrawn
Phase 4
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Start of enrollment: 2007 Oct 01
Withdrawn
Phase 4
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension Start of enrollment: 2008 Jul 01
Completed
Phase 2
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension Start of enrollment: 2011 Jan 01
Completed
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Start of enrollment: 2009 Mar 01
Completed
Phase 4
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument Start of enrollment: 2013 Apr 01
Completed
Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Pulmonary Hemodynamics During Exercise - Research Network Start of enrollment: 2018 Dec 01
Recruiting
Roles: Contact
Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19 Start of enrollment: 2020 Jul 13
Completed
Not Applicable
Effect of iNO in Patients With Submassive and Massive PE Start of enrollment: 2021 Jun 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Preacinar Arterial Dilation Mediates Outcomes of Quantitative Interstitial Abnormalities in the COPDGene Study.
Eileen M Harder, Pietro Nardelli, Carrie L Pistenmaa, Samuel Y Ash, Aparna Balasubramanian
American Journal of Respiratory and Critical Care Medicine. 2024-11-01
Management and outcomes in pulmonary arterial hypertension patients with sepsis.
Spencer Flynn, Haidee Chen, Russell Kerbel, Summer Gupta, Sonia Jasuja
BMC Pulmonary Medicine. 2024-10-28
Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension.
Jason Hong, Lejla Medzikovic, Wasila Sun, Brenda Wong, Grégoire Ruffenach
Circulation. 2024-10-15

Press Mentions

New Insights and Potential Treatments for Pulmonary HypertensionAugust 21st, 2024
I'm Aware That I'm Rare: The Phaware® PodcastApril 10th, 2024